Please assess the completion status of the following clinical trial:

Trial Title: MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute pulmonary edema with dyspnoea and anxiety~Exclusion Criteria:~* Patients with known severe liver disease.~* Patients with known severe renal disease.~* Patients with expectation of death from other illness during the course of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- midazolam (Type: EXPERIMENTAL): The dose of midazolam intravenously will be of 1 mg which may be repeated until a total dose of 3 mg.
- morphine (Type: ACTIVE_COMPARATOR): The dose of morphine intravenously is of 2-4 mg which may be repeated until a total dose of 8 mg if the patient continue suffering from severe anxiety or distress caused by APE

Based on this trial design, predict the completion outcome and termination type (if applicable).